Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination product containing **ibuprofen**, a nonsteroidal anti-inflammatory drug (NSAID), and **gamma-aminobutyric acid (GABA)**, an endogenous inhibitory neurotransmitter. Ibuprofen acts as a cyclooxygenase (COX) inhibitor to reduce prostaglandin synthesis, thus providing analgesic, anti-inflammatory, and antipyretic effects. Gamma-aminobutyric acid acts on GABA receptors in the central nervous system, leading to neuronal inhibition, though its efficacy as an oral supplement for pain or inflammation is not well established. The combination aims to manage pain and inflammation through both peripheral anti-inflammatory mechanisms (ibuprofen) and potential central neuromodulatory effects (GABA). Some formulations are marketed for dietary management of pain and inflammatory conditions[2][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ibuprofen + gamma-aminobutyric acid.